A catalyst for Canadian life sciences leading the world. Scroll down to find out how we do this. We proactively identify and evaluate. Therapeutically promising and commercially relevant early-stage technologies within academia and Canadian life sciences companies. We replicate data, and build interdisciplinary. Teams of experts to define and execute critical.

Avoir un impact significatif dans le traitement du cancer. Un modèle de recherche unique. Mécanismes de la morphogénèse cellulaire au cours de la mitose et de la migration. Structure et fonction du noyau cellulaire. Album photo du Concours de recrutement étudiant 2017. Album photo du concours de recrutement étudiant 2016.

GVHD Prediction and Prevention by Donor Gene Expression Profiling. Novel Adoptive Immunotherapy Approach through MiHA Targeting.

Novel Prognostic Classification of AML. Novel Prognostic Classification of AML. Is a particularly lethal form of cancer, with most patients dying within two years of diagnosis. It is one of the leading causes of death among young adults. Existing prognostic tests are often inaccurate, leaving doctors with no tools to guide their decision making about treatment options. A delegation from our team will be presenting.

Stem cell expansion for leukemia. Stem cell expansion for leukemia. ExCellThera is a clinical stage biotechnology company that is focused on developing robust and cost effective ways of growing blood stem cells for therapeutic use. We are working diligently to bring these new therapies to patients. CFO Please visit Our Team.